cinacalcet has been researched along with Bone Diseases, Metabolic in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 23 (71.88) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Ahmad, RA; Alhasan, KA; Kari, JA; Sheerah, AA | 1 |
| Ito, M; Koshika, M; Kudo, K; Masakane, I; Nishida, H; Nishida, W; Tanida, H; Tomita, Y | 1 |
| Kitazono, T; Tsuruya, K; Yamada, S | 1 |
| Moe, SM; Thadhani, R | 1 |
| Block, GA; Chertow, GM; Correa-Rotter, R; Dehmel, B; Drüeke, TB; Floege, J; Goodman, WG; Herzog, CA; London, GM; Mahaffey, KW; Modafferi, DM; Moe, SM; Parfrey, PS; Trotman, ML; Wheeler, DC | 1 |
| Cozzolino, M; Goldsmith, D; Ketteler, M; Khan, S; Martin, KJ; Sharma, A | 1 |
| Ayav, C; Brunaud, L; Erpelding, ML; Filipozzi, P; Frimat, L; Kessler, M | 1 |
| Behets, GJ; D'Haese, PC; De Broe, ME; Goodman, WG; Spasovski, G; Spiegel, DM; Sterling, LR | 1 |
| Abdelrahman, M; Abdulkader, M; Algareeb, A; Awn, NM; Karkar, A; Mushtaque, F; Nassar, M; Qadi, Y; Sabry, A; Shaheen, FA; Sinha, AK; Souqiyyeh, MZ; Taha, MI | 1 |
| Acosta Martínez, Y; Borrego Utiel, FJ; Bravo Soto, JA; García Álvarez, T; González Carmelo, I; López Jiménez, V; Mazuecos Blanca, MA; Merino Pérez, MJ | 1 |
| Ito, T; Iwashita, Y; Shigematsu, T | 1 |
| Ballarin, J; Bover, J; DaSilva, I; Diaz-Encarnacion, MM; Fernández, E; Lloret, MJ; Mateu, S; Mercado, C; Ruiz, C; Ureña-Torres, P | 1 |
| Covit, A; Pepe, J; Shastri, J; Sherman, RA; Tran, A | 1 |
| Bahner, U; Brandl, M; Nies, C; Schmidt-Gayk, H | 1 |
| Hamano, T | 2 |
| Fukagawa, M; Suzuki, M | 1 |
| Fukagawa, M; Komaba, H; Nakai, K | 1 |
| Shaheen, FA; Souqiyyeh, MZ | 1 |
| Andres, A; Gutierrez, E; Morales, E | 1 |
| Yokoyama, K | 1 |
| Taniguchi, M | 1 |
| Koiwa, F; Maruta, Y | 1 |
| Kakuta, T; Uemura, K | 1 |
| Lewin, E; Olgaard, K; Silver, J | 1 |
| Akizawa, T; Mizobuchi, M; Nakazawa, A | 1 |
| Jiang, W; Li, D; Shao, L; Xu, Y; Zhang, W; Zhou, H | 1 |
| Imanishi, Y | 1 |
| Akizawa, T; Fukagawa, M; Fukuhara, S; Fukuma, S; Hasegawa, T; Kurokawa, K; Onishi, Y; Yamaguchi, T | 1 |
| Alvarez-Ude, F; Arenas, MD; Carretón, MA; Devesa, R; Gil, MT; Malek, T; Moledous, A; Nuñez, C; Soriano, A | 1 |
| Brancaccio, D; Cozzolino, M; Galassi, A | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
15 review(s) available for cinacalcet and Bone Diseases, Metabolic
| Article | Year |
|---|---|
What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcimimetic Agents; Cardiovascular Diseases; Cinacalcet; Ergocalciferols; Humans; Hyperparathyroidism, Secondary; Naphthalenes; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
[Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
Topics: Bone and Bones; Bone Diseases, Metabolic; Calcimimetic Agents; Calcinosis; Calcium Carbonate; Cardiovascular Diseases; Cinacalcet; Ferric Compounds; Fractures, Bone; Humans; Minerals; Parathyroidectomy; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Risk Factors; Sevelamer | 2016 |
Integral pharmacological management of bone mineral disorders in chronic kidney disease (part II): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Topics: Bone Diseases, Metabolic; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Minerals; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Vitamin D | 2016 |
[Chronic kidney disease (CKD) and bone. Control of CKD-MBD from the viewpoint of the medical cost].
Topics: Bone Diseases, Metabolic; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Costs and Cost Analysis; Economics, Pharmaceutical; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroidectomy; Policy Making; Polyamines; Sevelamer; Vitamin D | 2009 |
Management of mineral and bone disorder in chronic kidney disease: quo vadis?
Topics: Bone Diseases, Metabolic; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Vitamin D; Vitamins | 2009 |
Treatment with calcimimetics in kidney transplantation.
Topics: Bone Diseases; Bone Diseases, Metabolic; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Graft Survival; Humans; Hypercalcemia; Hyperparathyroidism; Hypophosphatemia; Kidney Transplantation; Minerals; Naphthalenes; Postoperative Complications; Survival Analysis; Vitamin D Deficiency | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). The impact of CKD-MBD on mortality].
Topics: Bone Diseases, Metabolic; Calcinosis; Calcium; Chronic Disease; Cinacalcet; Humans; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Polyamines; Prognosis; Risk; Sevelamer; Survival Rate; Vascular Diseases; Vitamin D | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of cinacalcet in the treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Calcinosis; Calcium; Chronic Disease; Cinacalcet; Clinical Trials as Topic; Drug Therapy, Combination; Fractures, Bone; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Vascular Diseases; Vitamin D | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Parathyroid interventions: final one piece in the management of uremic SHPT patients].
Topics: Bone Diseases, Metabolic; Calcitriol; Chelating Agents; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroidectomy; Polyamines; Practice Guidelines as Topic; Receptors, Calcium-Sensing; Sevelamer; Uremia; Vitamin D | 2010 |
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D | 2011 |
The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcification, Physiologic; Calcimimetic Agents; Calcium, Dietary; Chelating Agents; Cinacalcet; Combined Modality Therapy; Dietary Supplements; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Naphthalenes; Peritoneal Dialysis; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Vitamin D | 2013 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Bone fragility in the aged hemodialysis patients].
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diphosphonates; Fractures, Spontaneous; Homeostasis; Humans; Kidney Diseases; Minerals; Naphthalenes; Osteoporosis; Phosphorus; Renal Dialysis; Risk | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Humans; Kidney Diseases; Lanthanum; Minerals; Naphthalenes; Parathyroidectomy; Polyamines; Sevelamer; Vitamin D | 2012 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
3 trial(s) available for cinacalcet and Bone Diseases, Metabolic
| Article | Year |
|---|---|
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial.
Topics: Adult; Aged; Bone Diseases, Metabolic; Calcimimetic Agents; Cinacalcet; Combined Modality Therapy; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroidectomy; Proportional Hazards Models; Renal Dialysis; Severity of Illness Index | 2013 |
Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cinacalcet; Dose-Response Relationship, Drug; Ergocalciferols; Female; Fibroblast Growth Factor-23; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Injections, Intravenous; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Diseases, Metabolic; Bone Resorption; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Osteogenesis; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Young Adult | 2015 |
14 other study(ies) available for cinacalcet and Bone Diseases, Metabolic
| Article | Year |
|---|---|
Cinacalcet use in pediatric chronic kidney disease. A survey study.
Topics: Age Factors; Bone Diseases, Metabolic; Child; Child, Preschool; Cinacalcet; Female; Humans; Hyperparathyroidism; Infant; Male; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Surveys and Questionnaires; Treatment Outcome | 2020 |
Chronic hemodialysis patients without marked elevation of intact parathyroid hormone are also good candidates for early intervention with cinacalcet.
Topics: Adult; Aged; Algorithms; Bone Diseases, Metabolic; Calcimimetic Agents; Calcium; Cinacalcet; Female; Humans; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Sterols; Time Factors; Vitamin D | 2013 |
Regression of tumoral calcinosis after the appropriate control of a deranged mineral and bone metabolism, in conjugation with cinacalcet hydrochloride treatment, in a chronic hemodialysis patient.
Topics: Bone Diseases, Metabolic; Calcimimetic Agents; Calcinosis; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Renal Dialysis; Treatment Outcome; Uremia | 2013 |
Influence on quality of life from an early cinacalcet prescription for secondary hyperparathyroidism in dialysis.
Topics: Aged; Aged, 80 and over; Bone Diseases, Metabolic; Cinacalcet; Dialysis; Drug Administration Schedule; Female; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Quality of Life | 2015 |
Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
Topics: Adult; Aged; Biomarkers; Bone Diseases, Metabolic; Chelating Agents; Cinacalcet; Cost-Benefit Analysis; Dietary Supplements; Drug Costs; Female; Humans; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Saudi Arabia; Time Factors; Treatment Outcome; Up-Regulation; Vascular Calcification; Vitamin D | 2014 |
Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Topics: Adult; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitriol; Calcium; Cinacalcet; Drug Substitution; Drug Therapy, Combination; Ergocalciferols; Female; Follow-Up Studies; Humans; Hyperparathyroidism, Secondary; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Postoperative Complications; Retrospective Studies | 2015 |
Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
Topics: Bone and Bones; Bone Diseases, Metabolic; Calcium; Cinacalcet; Female; Guideline Adherence; Humans; Kidney Failure, Chronic; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Practice Guidelines as Topic; Quality of Health Care; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vitamin D | 2008 |
Use of cinacalcet HCl to achieve the recommended targets of bone metabolism in a patient with therapy-resistant renal hyperparathyroidism.
Topics: Adult; Bone Diseases, Metabolic; Calcium; Cinacalcet; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Kidney Transplantation; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Treatment Outcome; Weight Gain | 2008 |
Emerging roles of cinacalcet hydrochloride in the management of CKD-MBD.
Topics: Bone Diseases, Metabolic; Cinacalcet; Humans; Kidney Failure, Chronic; Naphthalenes; Parathyroid Hormone; Renal Dialysis; Terminology as Topic | 2009 |
Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Topics: Attitude of Health Personnel; Biomarkers; Bone Diseases, Metabolic; Calcium; Chelating Agents; Chronic Disease; Cinacalcet; Evidence-Based Medicine; Glomerular Filtration Rate; Guideline Adherence; Health Care Surveys; Health Knowledge, Attitudes, Practice; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Diseases; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Guidelines as Topic; Practice Patterns, Physicians'; Renal Dialysis; Saudi Arabia; Surveys and Questionnaires; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2010 |
Calcimimetics, vitamin D and ADVANCE in the management of CKD-MBD.
Topics: Bone Diseases, Metabolic; Calcinosis; Cinacalcet; Humans; Kidney Failure, Chronic; Naphthalenes; Prognosis; Renal Dialysis; Vitamin D; Vitamins | 2011 |
Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study.
Topics: Aged; Biomarkers; Bone Diseases, Metabolic; Calcimimetic Agents; Calcium; Cinacalcet; Drug Prescriptions; Drug Utilization; Drug Utilization Review; Female; Humans; Hyperparathyroidism, Secondary; Japan; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphorus; Practice Patterns, Physicians'; Prevalence; Prospective Studies; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vitamin D | 2012 |
Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Topics: Bone and Bones; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Female; Humans; Hyperparathyroidism; Kidney Diseases; Male; Middle Aged; Naphthalenes; Practice Guidelines as Topic; Renal Dialysis; Vitamin D | 2007 |
Cinacalcet, paricalcitol, or both?
Topics: Bone and Bones; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Data Interpretation, Statistical; Drug Therapy, Combination; Humans; Hyperparathyroidism; Kidney Diseases; Naphthalenes; Practice Guidelines as Topic; Renal Dialysis; Vitamin D | 2007 |